NCT04371224招募中2 期
Randomized Phase II Study of NaliCap (Irinotecan Liposome/Capecitabine) Compared to NAPOLI (Irinotecan Liposome/5-fluorouracil/Leucovorin) in Gemcitabine-pretreated Advanced Pancreatic Cancer
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 200
- 试验地点
- 2
- 主要终点
- Progression-free survival
研究概览
简要总结
This is an open label, randomized phase 2 study of NaliCap (irinotecan liposome/Capecitabine) compared to NAPOLI (irinotecan liposome/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer patients.
详细描述
- At the time of initial diagnosis of pancreatic cancer, resectable pancreatic cancer is around 20%, locally-advanced pancreatic cancer is around 25-30%, and the remaining is metastatic pancreatic cancer.
- In metastatic pancreatic cancer, Gemcitabine/Abraxane or FOLFIRINOX 5-fluorouracil/leucovorin/irinotecan/oxaliplatin (FOLFIRINOX) is most commonly used regimen as a palliative 1st-line chemotherapy. In gemcitabine-pretreated pancreatic cancer, irinotecan liposome(nal-IRI)/5-fluorouracil(5FU)/leucovorin(LV)(NAPOLI regimen) improved overall survival of patients compared to 5FU/LV. Now, NAPOLI is standard of care in gemcitabine-pretreated pancreatic cancer.
- Oral 5-FU such as TS-1 is used in gemcitabine pretreated pancreatic cancer patients or 1st-line treatment in gemcitabine-intolerable patients.
- Capecitabine is oral 5-FU, which is commonly used in GI cancers, usually replacing intravenous infusion of 5-FU. It improves patient's convenience not requiring vascular access or hospital admission.
- In NAPOLI regimen, iv 5-FU/LV could be replaced with capecitabine. So far, nal-IRI/Capecitabine combination has not yet been tested.
- Based on these rationale, we plan to conduct the open-label, randomized phase 2 study to assess the safety and efficacy of NaliCap (nal-IRI/Capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in patients with gemcitabine-pretreated advanced pancreatic cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent
- •Age>20 years at time of study entry
- •Histologically confirmed pancreatic ductal adenocarcinoma
- •Advanced stage (unresectable, recurrent)
- •Gemcitabine-pretreated for advanced pancreatic cancer
- •Eastern Cooperative Oncology Group(ECOG) performance status 0, 1
- •Adequate organ function
- •Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal subjects.
- •Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
排除标准
- •Participation in another clinical study with an investigational product (IP) during the last 3 weeks
- •Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study
- •Receipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) 28 days prior to the first dose of study drug
- •Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable.
- •Known brain metastasis or spinal cord compression.
- •History of allogenic organ transplantation
- •Cardiac event during past 6 months
- •Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
- •Active infection including tuberculosis (TB) (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive hepatitis B virus (HBV) surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc (hepatitis B core antigen)] and absence of HBsAg) are eligible. Subjects positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
- •Female subjects who are pregnant or breastfeeding or male or female subjects of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of IP.
- •Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
- •Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements.
研究组 & 干预措施
NaliCap
Experimental
nal-IRI/Capecitabine
干预措施: Irinotecan Liposomal Injection [Onivyde] (Drug)
NaliCap
Experimental
nal-IRI/Capecitabine
干预措施: Capecitabine (Drug)
NAPOLI
Active Comparator
nal-IRI/5-FU/LV
干预措施: Irinotecan Liposomal Injection [Onivyde] (Drug)
NAPOLI
Active Comparator
nal-IRI/5-FU/LV
干预措施: 5-fluorouracil (Drug)
NAPOLI
Active Comparator
nal-IRI/5-FU/LV
干预措施: Leucovorin (Drug)
结局指标
主要结局
Progression-free survival
时间窗: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
Progression-free survival was defined as the duration between randomization and disease progression, any cause of death before disease progression, or the last follow-up.The event was defined as disease progression and any cause of death.
次要结局
- Overall survival(From date of randomization until the date of first documented date of death from any cause, whichever came first, assessed up to 12 months)
- Objective response rate(through study completion, an average of 1 year)
- Adverse events(through study completion, an average of 1 year)
- QOL: eortc qlq-c30(through study completion, an average of 1 year)
研究者
Do-Youn Oh
Professor
Seoul National University Hospital
研究点 (2)
Loading locations...
相似试验
尚未招募
不适用
Randomized phase II study of NaliCap (nal-IRI/Capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in Gemcitabine-pretreated advanced pancreatic cancerNeoplasmsKCT0004845Seoul National University Hospital200
已完成
2 期
Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or ChemoradiotherapyHead & Neck CancerNCT03712397National Health Research Institutes, Taiwan59
进行中（未招募）
1 期
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary CancerMetastatic Biliary Tract CarcinomaMetastatic Colorectal CarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaMetastatic Malignant Digestive System NeoplasmMetastatic Pancreatic AdenocarcinomaStage IV Colorectal Cancer AJCC v7Stage IV Pancreatic Cancer AJCC v6 and v7Stage IVA Colorectal Cancer AJCC v7Stage IVB Colorectal Cancer AJCC v7NCT03337087Academic and Community Cancer Research United18
进行中（未招募）
2 期
Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric CancerEsophageal CancerNCT03764553Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)320
终止
2 期
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract CancerAdvanced Biliary Tract CancerExtrahepatic CholangiocarcinomaGallbladder CarcinomaIntrahepatic CholangiocarcinomaNCT05009953CSPC Ouyi Pharmaceutical Co., Ltd.17